Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon

Journal of the National Cancer Institute

Volumn 101, Issue 12, 2009, Pages 869-877

  Bouwhuis, Marna G ^a   Suciu, Stefan ^b   Collette, Sandra ^b   Aamdal, Steinar ^c   Kruit, Wim H ^a   Bastholt, Lars ^d   Stierner, Ulrika ^e   Sals, Franois ^f   Patel, Poulam ^g   Punt, Cornelis J A ^h   Hernberg, Micaela ⁱ   Spatz, Alain ^j   Ten Hagen, Timo L M ^a   Hansson, Johan ^k   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Statistics Department   (Belgium)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f JULES BORDET INSTITUTE   (Belgium)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; THYROGLOBULIN ANTIBODY; ALPHA INTERFERON; ALPHA2 INTERFERON; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; IMMUNOLOGICAL ADJUVANT; INTERFERON-ALPHA 2;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE RISK; SEROCONVERSION; BLOOD; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK; SKIN TUMOR; TIME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; TIME FACTORS;

EID: 67449138506     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp132     Document Type: Article

References (26)

1. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004; 10 (5): 1670-1677.
2. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003; 29 (4): 241-252.
3. Wheatley K, Ives N, Eggermont A, et al. Interferon alpha as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol. 2007; 25 (suppl): 8526.
4. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354 (7): 709-718.
5. Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer. 2007; 121 (11): 2562-2566.
6. Polman CH, Kappos L, Dahlke F, et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology. 2005; 64 (6): 996-1000.
7. Shovman O, Gilburd B, Barzilai O, et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci. 2005; 1050 (June): 380-388.
8. Solans-Laque R, Perez-Bocanegra C, Salud-Salvia A, et al. Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus. 2004; 13 (3): 159-164.
9. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997; 40 (9): 1601-1611.
10. Imran A, Neelam F, Tariq M. Incidence of circulating antinuclear antibodies in cancer patients. Indian J Med Sci. 2003; 57 (3): 113-116.
11. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005; 366 (9492): 1189-1196.
12. Hansson J, Aamdal S, Bastholt L, et al. Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma. Eur J Cancer. 2007; 6 (suppl 5): 4.
13. Smeenk RJ, Lucassen WA, Swaak TJ. Is anticardiolipin activity a crossreaction of anti-DNA or a separate entity? Arthritis Rheum. 1987; 30 (6): 607-617.
14. van Dam AP, Wekking EM, Callewaert JA, et al. Psychiatric symptoms before systemic lupus erythematosus is diagnosed. Rheumatol Int. 1994; 14 (2): 57-62.
15. Kalbfleisch JD, Prentice RL. The Survival Analysis of Failure Time Data. 2nd ed. Hoboken, NJ: Wiley Inter Science; 2002.
16. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983; 1 (11): 710-719.
17. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988; 318 (24): 1557-1563.
18. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with meta-static melanoma. J Clin Oncol. 2001; 19 (15): 3477-3482.
19. Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993; 11 (7): 1376-1383.
20. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19 (16): 3622-3634.
21. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993; 43 (10): 2069-2073.
22. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol. 1989; 16 (5): 623-625.
23. Ozpoyraz N, Tamam L, Kulan E. Thyroid abnormalities in lithium-treated patients. Adv Ther. 2002; 19 (4): 176-184.
24. Pamuk ON, Cakir N. The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms. Clin Rheumatol. 2007; 26 (1): 55-59.
25. Punzi L, Ostuni PA, Betterle C, De Sandre P, Botsios C, Gambari PF. Thyroid gland disorders in primary Sjogren's syndrome. Rev Rhum Engl Ed. 1996; 63 (11): 809-814.
26. Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke. 1995; 26 (5): 749-754.